GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (STU:3371) » Definitions » Ending Cash Position

Corbus Pharmaceuticals Holdings (STU:3371) Ending Cash Position : €17.06 Mil (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Ending Cash Position?

Corbus Pharmaceuticals Holdings's Ending Cash Position for the quarter that ended in Dec. 2024 was €17.06 Mil.

Corbus Pharmaceuticals Holdings's quarterly Ending Cash Position declined from Jun. 2024 (€22.63 Mil) to Sep. 2024 (€18.10 Mil) and declined from Sep. 2024 (€18.10 Mil) to Dec. 2024 (€17.06 Mil).

Corbus Pharmaceuticals Holdings's annual Ending Cash Position declined from Dec. 2022 (€16.68 Mil) to Dec. 2023 (€13.20 Mil) but then increased from Dec. 2023 (€13.20 Mil) to Dec. 2024 (€17.06 Mil).


Corbus Pharmaceuticals Holdings Ending Cash Position Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings Ending Cash Position Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.06 22.72 16.68 13.20 17.06

Corbus Pharmaceuticals Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.20 13.59 22.63 18.10 17.06

Corbus Pharmaceuticals Holdings Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Corbus Pharmaceuticals Holdings's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=13.746+3.318
=17.06

Corbus Pharmaceuticals Holdings's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=19.189+-2.125
=17.06


Corbus Pharmaceuticals Holdings Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Corbus Pharmaceuticals Holdings Business Description

Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings Headlines

No Headlines